An advisory committee for the US Food and Drug Administration (FDA) determined that the  drug solithromycin is an effective treatment for pneumonia.

A U.S. Food and Drug Administration advisory committee hearing Friday concluded positively for Chapel Hill-based Cempra’s pneumonia drug solithromycin.

The committee voted 7-6 in favor of the drug, Reuters reports. The panel found that the drug – which the company says is not susceptible to antibiotic resistance – is an effective treatment for community acquired pneumonia.

According to Reuters, the committee concluded that the benefits of the drug for such treatment outweigh the risks of hepatotoxicity, or liver damage. It advised the company to collect additional data for risk assessment.

Cempra’s stock trading halted Friday awaiting results of the hearing.

View the full story at